Please login to the form below

Not currently logged in
Email:
Password:

HAE

This page shows the latest HAE news and features for those working in and with pharma, biotech and healthcare.

Shire’s angioedema drug Takhzyro claims EU approval

Shire’s angioedema drug Takhzyro claims EU approval

The company maintains that Takhzyro has the potential to expand the HAE prevention market, particularly in international markets, as it is easier to administer than other drugs. ... Analysts at Bernstein recently predicted that Takhzyro will eventually

Latest news

  • Shire’s angioedema drug Takhzyro recommended in Europe Shire’s angioedema drug Takhzyro recommended in Europe

    Takhzyro has been recommended for prevention of recurrent attacks of hereditary angioedema (HAE) a rare, genetic disorder that results in recurring attacks of oedema in parts of the body, including the ... The drug isn’t the first HAE treatment on the

  • Shire claims US okay for HAE blockbuster-in-waiting Shire claims US okay for HAE blockbuster-in-waiting

    community. “HAE attacks are painful, debilitating, and potentially life threatening,” commented Anthony Castaldo, president of the US Hereditary Angioedema Association. ... Takhzyro provides the HAE community with a new option for the prevention of

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    Shire recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE) therapy Cinryze and has three new therapies filed for approval, namely lanadelumab for ... HAE, prucalopride (SHP555) for

  • EMA starts rapid review of Shire’s HAE antibody EMA starts rapid review of Shire’s HAE antibody

    two weeks resulted in an 87% reduction in the mean frequency of HAE attacks overall, according to Shire. ... Other approved treatments for HAE include CSL Behring’s Berinert and Pharming’s Ruconest.

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    The pipeline will focus on therapy areas including haematology, immunology, neuroscience, lysosmal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE), and brings Baxalta's haemophilia franchise into the fold.

More from news
Approximately 5 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • A rare talent A rare talent

    and HAE.”.

  • Deal Watch November 2015 Deal Watch November 2015

    Given that Shire's Cinryze is already approved in HAE, It will be interesting to see what the regulators say on the anti-competition front. ... 160, 000. Dyax Corporation. Shire. Acquisition - company. Includes KALBITOR marketed for acute attacks of HAE

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics